je.st
news
Tag: merck
US FDA Accepts for Review a Biologics License Application for Merck and Sanofi Pasteurs Investigational Pediatric Hexavalent Vaccine
2014-10-20 14:00:00| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. & SWIFTWATER, Pa. Phase III clinical study data presented at IDWeek in Philadelphia WHITEHOUSE STATION, N.J. & SWIFTWATER, Pa.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT:SAN and NYSE:SNY), announced today that the Biologics License Application (BLA) filed for the companies investigational pediatric hexavalent vaccine, DTaP5-IPV-Hib-HepB1, has been accepted for review by the U.S. Food and Drug Administration (FDA). Language: English Contact: MerckMedia:Deb Wambold, (215) 652-2913orInvestors:Justin Holko, (908) 423-5088orSanofi PasteurMedia:Susan Watkins, (570) 957-2563susan.watkins@sanofipasteur.comorInvestors:George Grofik, (908) 981-5560IR@sanofi.com Ticker Slug: Ticker: MRK Exchange: NYSE Ticker: SAN Exchange: BOURSE Ticker: SNY Exchange: NYSE read more
Tags: review
application
license
accepts
Roche, Merck extend immunotherapy fight to breast cancer
2014-10-18 04:23:46| Biotech - Topix.net
Swiss drugmaker Roche and U.S. group Merck & Co are to present data on their rival immunotherapy drugs in breast cancer in December, extending the novel approach to fighting tumors to another cancer type. Early clinical results with Roche's drug, known as MPDL3280A, in so-called triple negative breast cancer will be revealed at the Dec. 9-13 San Antonio Breast Cancer Symposium, the firm said after announcing third-quarter results.
Tags: fight
cancer
extend
breast
Merck Announces Final Results of Tender Offers for Eight Series of Notes
2014-10-15 14:00:00| Merck.com - Corporate News
Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck & Co., Inc. (Merck) (NYSE:MRK), known as MSD outside the United States and Canada, announced today the final results of the previously announced offers to purchase (collectively, the Offers) any and all of the outstanding notes listed in the table below (collectively, the Notes). On Oct. 6, 2014, Merck commenced the Offers in accordance with the terms and conditions set forth in the Offer to Purchase, dated Oct. 6, 2014 (the Offer to Purchase). Language: English Contact: Merck & Co., Inc.Media:Steve Cragle, (908) 423-3461Lainie Keller, (908) 236-5036orInvestors:Joe Romanelli, (908) 423-5185Justin Holko, (908) 423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Merck Announces Pricing of Tender Offers for Eight Series of Notes
2014-10-15 00:20:00| Merck.com - Corporate News
Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck & Co., Inc. (Merck) (NYSE:MRK), known as MSD outside the United States and Canada, announced today the pricing of the previously announced offers to purchase (collectively, the Offers) any and all of the outstanding notes listed below (collectively, the Notes). The Offers are being made upon, and are subject to, the terms and conditions set forth in the Offer to Purchase, dated Oct. 6, 2014 (Offer to Purchase). Language: English Contact: Merck & Co., Inc.Media:Steve Cragle, 908-423-3461Lainie Keller, 908-236-5036orInvestor Contacts:Joe Romanelli, 908-423-5185Justin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Merck - Counting on the Pipeline to Revive Its Fortunes
2014-10-09 21:12:33| Footwear - Topix.net
Right now, Merck , this nation's second biggest pharmaceutical maker, is a curious animal: a value stock that's priced like a growth stock. It's almost enough to for me to put a "Sell" recommendation on the stock, but not quite.
Tags: to
counting
pipeline
merck
Sites : [66] [67] [68] [69] [70] [71] [72] [73] [74] [75] [76] [77] [78] [79] [80] [81] [82] [83] [84] [85] next »